All In Biotech

Drug Trial Radar · NCT00081744

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects

Last checked: Nov 19, 2026Latest source record: Feb 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

850

Actual

Start

Nov 2002

Primary completion

Aug 2004

Study completion Aug 2004

Sponsor

Sponsor type
Industry
First posted
Apr 21, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.

Conditions

  • Gram-Positive Bacterial Infections
  • Cross Infection

Interventions

  • TigecyclineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.